MB-105 in Patients With CD5 Positive T-cell Lymphoma

This study tests MB-105 — a CAR-T cell therapy targeting a protein called CD5 — in patients with relapsed or refractory T-cell lymphoma (TCL), a rare and often aggressive type of lymphoma that starts in T-cells (immune cells). Because CD5 is found on most T-cell lymphoma cells, CAR-T therapy targeting it may be effective in cancers that have stopped responding to other treatments. This study evaluates safety and initial effectiveness. **You may be eligible if...** - You are 18 or older with T-cell lymphoma (either cutaneous T-cell lymphoma or peripheral T-cell lymphoma) that has relapsed or is refractory - Your tumor tests positive for CD5 protein (at least 50% of cells, or you may qualify for an exploratory group with lower expression) - You have measurable disease on a scan - You have received at least 1 (PTCL) or 2 (CTCL) prior standard treatments - Your heart, lung, kidney, and liver function meet minimum thresholds - Your blood counts are within required ranges **You may NOT be eligible if...** - You had a prior stem cell transplant or CAR-T therapy within the past 60 days - You have active Graft versus Host Disease - You have an active serious infection - You have significant heart or other organ failure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.